Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1][2] - Among the CFOs, those aged 40-50 constitute the majority at 36%, while 5% are over 60 years old, 33% are aged 50-60, and 26% are 40 years old or younger [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, 12% have an associate degree, and only 2% have a high school education [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The distribution of salaries indicates that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - Among the CFOs, those aged 40-50 represent the majority at 36%, while those aged 60 and above account for 5% [1] - The youngest CFO currently in office is 33 years old, from XinNuoWei, named Dai Long [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, while another 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - Among the CFOs, those aged 40-50 represent the core strength of the market, accounting for 36%, while those aged 60 and above account for 5% [1] - The youngest CFO currently in office is 33 years old, from XinNuoWei, named Dai Long [1] Group 2 - The average annual salary of CFOs in A-share raw material drug companies is 661,200 yuan, with 44% earning below 500,000 yuan and another 44% earning between 500,000 and 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2] - The largest salary decrease was observed for Liu Qingke from Huangshan Capsule, with a year-on-year decline of 19.04%, while the largest salary increase was for Qian Dan from Nengte Technology, with a year-on-year increase of 100.58% [2]

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total salary scale for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Salary Distribution - The average salary for CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan, with 44% earning below 500,000 yuan, 44% between 500,000 and 1 million yuan, and 12% above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2] CFO Age Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 50-60 account for 33%, and those aged 40 and below make up 26%. Only 5% of CFOs are over 60 years old [1] CFO Educational Background - The educational background of CFOs shows that 2% have a high school diploma, 12% have an associate degree, 65% hold a bachelor's degree, and 21% possess a master's degree. Notably, only one CFO has a high school education [1] Salary Changes - Among CFOs with over two years of tenure, Liu Qingke from Huangshan Capsule experienced the largest salary decrease of 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase of 100.58% [2]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 其中，年薪排行前三的CFO分别为国邦医药的龚裕达、浙江医药的李齐融、新华制药的侯宁，三人年薪 分别为193.09万元、184.18 万元、156.7万元。 从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），黄山胶囊的刘清科2024年薪酬降幅最大，同 比降幅达19.04%；能特科技的蹇丹薪酬增幅最大，同比涨幅达100.58%。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市原料药公司，其 聘任总体情况如下（部分统计口径剔除无效数据）。 责任编辑：公司观察 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到36%；60岁以上的CFO占比 为5%；50岁-60岁的CFO群体占比为33%；40岁及以下CFO群体占比为26%。其中，目前仍任职的最年 ...

来源：金融界 金融界2025年8月7日消息，中欧医疗健康混合A(003095) 最新净值1.9247元，下跌2.13%。该基金近1个 月收益率12.28%，同类排名748|4409；近6个月收益率24.19%，同类排名493|4271；今年来收益率 22.69%，同类排名997|4244。 中欧医疗健康混合A股票持仓前十占比合计54.73%，分别为：药明康德（10.39%）、恒瑞医药 （9.69%）、康龙化成（5.05%）、科伦药业（4.97%）、泰格医药（4.78%）、凯莱英（4.67%）、百利 天恒（4.11%）、信立泰（4.02%）、百济神州-U（3.66%）、新诺威（3.39%）。 公开资料显示，中欧医疗健康混合A基金成立于2016年9月29日，截至2025年6月30日，中欧医疗健康混 合A规模156.38亿元，基金经理为葛兰、赵磊。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至201 ...

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.3960 yuan, reflecting a decline of 2.19% [1] - The fund has shown a one-month return of 10.22%, a six-month return of 29.67%, and a year-to-date return of 29.08%, with respective rankings of 252 out of 1022, 86 out of 985, and 130 out of 975 in its category [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xinlitai (6.70%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan, managed by fund manager Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having served in various roles since joining ICBC Credit Suisse in 2010 [2]

Group 1 - The core point of the news is the performance and holdings of the Industrial and Commercial Bank of China (ICBC) Healthcare Stock Fund, which has shown significant returns over various time frames despite a recent decline in net value [1] - As of August 7, 2025, the fund's latest net value is 2.8960 yuan, reflecting a decrease of 2.03%. The fund has achieved a return of 10.32% over the past month, ranking 242 out of 1022 in its category. Over the last six months, the return is 26.13%, ranking 113 out of 985, and since the beginning of the year, the return is 27.07%, ranking 155 out of 975 [1] - The top ten holdings of the ICBC Healthcare Stock Fund account for a total of 44.59%, with significant positions in companies such as Heng Rui Medicine (7.52%), Kelun Pharmaceutical (6.50%), and BeiGene (5.08%) [1] Group 2 - The ICBC Healthcare Stock Fund was established on November 18, 2014, and as of June 30, 2025, it has a total scale of 2.797 billion yuan. The fund is managed by Zhao Bei and Ding Yang [1] - Zhao Bei holds a master's degree and has extensive experience in healthcare investment, having been with ICBC Credit Suisse since 2010 and managing the healthcare fund since its inception [2] - Ding Yang, a PhD holder, joined ICBC Credit Suisse in December 2017 and has been involved in managing various funds, including the healthcare sector since May 2023 [2]

Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A (007718) is 2.1723 yuan, reflecting a decline of 3.54%. The fund has shown a one-month return of 12.66%, a six-month return of 78.76%, and a year-to-date return of 80.53% [1]. Fund Performance - The fund ranks 684 out of 4457 in the one-month category, 23 out of 4316 in the six-month category, and 29 out of 4287 in the year-to-date category [1]. Holdings Overview - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 62.83%, with significant positions in companies such as: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Heng Rui Medicine (8.08%) - CanSino Biologics (8.07%) - New Horizon Health (6.13%) - Bai Li Tianheng (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino Biologics-B (3.91%) [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and has previously held positions at Taikang Asset Management and Zhonggeng Fund Management. He joined Zhongyin Fund Management in 2022 and has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022 [2].